# A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Source: https://onco.cc/trials/nct07157033/  
OnCo record `nct07157033` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of XER-001 in pancreatic ductal adenocarcinoma, run by Xerient Pharma, now recruiting.

## Summary

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. is a phase 1/2 interventional study registered as NCT07157033 by Xerient Pharma, with 36 participants planned, started 2026-01-01 and due to reach its primary completion in 2029-07-31. Interventions recorded: XER-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07157033
- Phase: 1/2
- Setting: A Phase 1/2a, Open Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of XER-001 (Amifostibe for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment of Locally-Advanced Pancreatic Adenocarcinoma
- Sponsor: Xerient Pharma
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07157033: https://clinicaltrials.gov/study/NCT07157033

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct07157033.json